What one share of Tempest Therapeutics holds
We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates.
Tempest Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.58 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.34 |
| Cash and investments | $0.05 |
| Book value | −$0.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$533.37 | $1.39 | −$529.46 | $0.00 | — |
| 2021 | — | −$97.07 | $0.46 | −$89.49 | — | $67.94 |
| 2022 | — | −$40.20 | $0.63 | −$35.61 | — | $22.38 |
| 2023 | — | −$24.87 | $0.14 | −$23.21 | — | $15.79 |
| 2024 | — | −$19.50 | $0.20 | −$15.59 | — | $5.65 |
| 2025 | — | −$6.33 | $0.00 | −$6.46 | — | $1.35 |
Common questions about Tempest Therapeutics
How much does one share of Tempest Therapeutics earn?
Over the last 12 months, Tempest Therapeutics lost $4.58 for each share.
Does Tempest Therapeutics pay a dividend?
Tempest Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Tempest Therapeutics’s book value per share?
Tempest Therapeutics’s book value is negative (−$0.07 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Tempest Therapeutics have?
Each share of Tempest Therapeutics has $0.05 of cash and investments, as of June 30, 2026.
What is Tempest Therapeutics’s free cash flow per share?
−$2.34 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Tempest Therapeutics bought back shares?
Tempest Therapeutics’s share count rose about 11423% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.